As the source of biotherapeutic production, the bioreactor is a crucial step for a successful bioprocess. Bioreactors must maintain precise control of environmental conditions to achieve optimal cell growth and productivity, requiring reproducible control strategies. The technology must be flexible and scalable to deliver consistent results from lab to manufacturing.
The Mobius® iFlex Bioreactor was developed to meet these requirements and deliver high performance for any process type, from fed-batch to high VCD perfusion. This presentation will demonstrate the system control capabilities in cell-free and cell-containing experiments, enabling successful upstream process outcomes.
In this webinar, you will learn:
- Cell-free methods that were used to evaluate strategies for pH and DO control.
- How a new bioreactor technology was designed with integrated process control for high-performance and scalability.
- Examples of cell culture processes that were successfully executed in the Mobius® iFlex Bioreactor.
Speakers
Haley Matthews
Merck
Applications Engineer II
Haley Matthews is an applications engineer in single-use and integrated systems R&D at Merck. Since joining the company in June of 2020, Haley has participated in the development, launch, and collateral generation for technologies such as the Cellicon® Cell Retention Filter, Mobius® Cell Retention System, and Mobius® iFlex Bioreactors. Haley holds a BS in bioengineering from University of Massachusetts Dartmouth and an MS in biotechnology from Worcester Polytechnic Institute.
Gujie Mi, Ph.D.
Merck
R&D Manager
Gujie Mi is an R&D manager within the single-use and integrated systems R&D team. Since joining the company in 2022, he has been leading a diverse team in developing, characterizing, and launching next generation single-use products and systems. These innovations meet the growing demands for high-throughput processing, process intensification, automation, and process control. Prior to his current role, Gujie worked in various biopharmaceutical companies, specializing in upstream process and technology development. He holds a Ph.D. in chemical engineering from Northeastern University.
Pharma and biopharma manufacturing
- Bioreactor Production
Duração:1h
Idioma:English
Sessão 1:apresentado September 5, 2024
Para continuar lendo, faça login ou crie uma conta.
Ainda não tem uma conta?